Citation

Gajwani P, Muzina DJ, Kemp DE, Gao K, Calabrese JR. Neuropsychiatr. Dis. Treat. 2007; 3(6): 847-853.

Copyright

(Copyright © 2007, Dove Press)

DOI

unavailable

PMID

unavailable

Abstract

The essential features of bipolar affective disorder involve the cyclical occurrence of high (manic or hypomanic episodes) and low mood states. Depressive episodes in both bipolar I and II disorder are more numerous and last for longer duration than either manic or hypomanic episodes. In addition depressive episodes are associated with higher morbidity and mortality. While multiple agents, including all 5 atypical antipsychotics, have demonstrated efficacy and earned US FDA indication for manic phase of bipolar illness, the acute treatment of bipolar depression is less well-studied. The first treatment approved by the US FDA for acute bipolar depression was the combination of the atypical antipsychotic olanzapine and the antidepressant fluoxetine. Recently, quetiapine monotherapy has demonstrated efficacy in the treatment of depressive episodes associated with both bipolar I and II disorder and has earned US FDA indication for the same. © 2007 Dove Medical Press Limited. All rights reserved.

Language: en

Keywords

United States; human; bipolar disorder; Bipolar disorder; mortality; suicide attempt; hospitalization; clinical trial; bipolar depression; disease severity; morbidity; article; disease association; fluoxetine; quetiapine; drug safety; placebo; food and drug administration; drug efficacy; extrapyramidal symptom; olanzapine; drug tolerability; weight gain; drug withdrawal; Hamilton scale; lorazepam; mania; side effect; hypomania; atypical antipsychotic agent; glucose blood level; drug indication; Quetiapine; disease duration; monotherapy; diagnostic and statistical manual of mental disorders; Montgomery Asberg Depression Rating Scale; drug dose titration; Clinical Global Impression scale; zolpidem tartrate; parallel design; drug dose comparison; bedtime dosage; BOLDER studies; effect size